The Road to QIBA Profile Conformance

Consensus Profiles & Confirmed Profiles



CT: MR: Lesions in four organs ADC-DW MR

Lung Tumor Volume (Adv Disease)

CT: Small Lung Nodule in CT Screening

Pilots Under Development

FDG-PET:

SUV

Solid Tumor

Self Attestation of Profile Conformance

✓ QIBA Profile checklist for the relevant actors Instructions on potential phantom and / or DRO tests Report template to confirm successful conformance test



QIBA Review of Report

QIBA Registered



These documents can be found on the QIBA Wiki



Pilot In Use

QIBA or Designee Tests for Conformance



Report Review by Testing Service

QIBA Certified



QIBA[®] Conformance Certification Mark

Our Pilots

SUV – FDG PET (for Solid Tumor Imaging):

The Profile claims that if FDG-PET/CT images are acquired with compliant equipment and procedures, the test-retest coefficient of variation of SUV_{MAX} is 10-12%. An equivalent statement is that if the second scan has an increase of +39% or more, or a decrease of -28% or more, then a true change in SUV_{MAX} has occurred with a 95% level of confidence.

Volume – CT (Tumor Advanced Disease):

The Profile improves the repeatability of tumor volume measurements in the thorax; for example, a measured 24% increase provides 95% confidence of progression for 50-100mm tumors.

ADC – DWI MR:

The DWI Profile assesses longitudinal change in tissue microstructure in response to therapy in brain, liver, breast, and prostate by providing knowledge of the expected variance of measurement of the apparent diffusion coefficient.



Value

- **Confidence in Analysis Tools**
- **Confidence in Scanner Performance**
- Harmonized data across time
- Harmonized data across sites



Robust Quantitative Data for Clinical Trials & Clinical Practice



We are looking for Early Adopters

Are you one of the following and interested?

- Clinical Site
- CRO
- Equipment Vendor
- Software Vendor

Please contact: **QIBA@rsna.org**

Authors: Gudrun Zahlmann, Edward F. Jackson, Alexander R. Guimaraes, Anne M. Smith, Annette Schmid, Richard L. Wahl, Daniel C. Sullivan, Paul E. Kinahan, Timothy G. Turkington, Jeffrey T. Yap, Michael A. Boss, Thomas L. Chenevert, Kevin O´Donnell, Nicholas Petrick, Ricardo Avila

Acknowledgements:

- Ongoing support by RSNA Leadership
- Various QIBA projects and activities have been funded in whole or in part with Federal funds from the National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Department of Health and Human Service, under Contracts Nos. HHSN268201000050C, HHSN268201300071C, and HHSN268201500021C